Physician profile
Ivan D Jackson
NPI 1205839362
$4,586.22
in general payments reported to CMS, 2019-2025
30 companies · $417 in 2025
The $417 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $416 · 2020: $146 · 2021: $367 · 2022: $997 · 2023: $1,200 · 2024: $1,045 · 2025: $417.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,661.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,660.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $630.11 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $494.26 | 2019-2024 | Trelegy Ellipta, Shingrix |
| Abbvie INC. | $449.64 | 2021-2025 | |
| Pfizer INC. | $355.54 | 2019-2024 | |
| Astellas Pharma US INC | $293.77 | 2019-2024 | Veozah, Myrbetriq |
| Amgen INC. | $266.06 | 2019-2024 | Repatha, Prolia, Evenity |
| Novo Nordisk INC | $242.84 | 2022-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $201.21 | 2022-2025 | Airsupra, Farxiga |
| Otsuka America Pharmaceutical, INC. | $198.67 | 2023-2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $170.96 | 2023-2025 | |
| Abbott Laboratories | $170.68 | 2022-2023 | Freestyle Libre 2 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $169.20 | 2019-2024 | Xifaxan, Trulance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $134.13 | 2019-2025 | Jardiance, Tradjenta |
| Takeda Pharmaceuticals U.S.A., INC. | $111.42 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $102.11 | 2020-2024 | Spravato, Xarelto |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $88.71 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $85.34 | 2019-2023 | Verquvo, Dificid, Belsomra |
| Amarin Pharma, INC. | $63.88 | 2021-2022 | |
| Almatica Pharma LLC | $59.90 | 2022 | |
| Corium, LLC | $53.71 | 2023 | Azstarys |
| Biohaven Pharmaceutical Holding Company LTD. | $49.69 | 2022 | |
| Phathom Pharmaceuticals, INC. | $33.12 | 2024 | Voquezna |
| Kowa Pharmaceuticals America, INC. | $30.58 | 2022-2024 | Livalo |
| Eisai INC. | $28.68 | 2021 | |
| Sumitomo Pharma America, INC. | $26.06 | 2025 | Gemtesa |
| Esperion Therapeutics, INC. | $17.69 | 2024 | Nexletol |
| Avanir Pharmaceuticals, INC. | $17.55 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $14.63 | 2022 | |
| Exact Sciences Corporation | $14.41 | 2023 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $11.67 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ivan Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.